TY - JOUR
T1 - The multiple facets of ovarian high grade serous carcinoma: A review on morphological, immunohistochemical and molecular features
AU - Santoro, Angela
AU - Angelico, Giuseppe
AU - Travaglino, Antonio
AU - Inzani, Frediano
AU - Spadola, Saveria
AU - Pettinato, Angela
AU - Mazzucchelli, Manuel
AU - Bragantini, Emma
AU - Maccio, Livia
AU - Zannoni, Gian Franco
PY - 2025
Y1 - 2025
N2 - High-grade serous ovarian carcinoma (HGSOC) is the most aggressive subtype of epithelial ovarian cancer and a leading cause of mortality among gynecologic malignancies. This review aims to comprehensively analyze the morphological, immunohistochemical, and molecular features of HGSOC, highlighting its pathogenesis and identifying biomarkers with diagnostic, prognostic, and therapeutic significance. Special emphasis is placed on the role of tumor microenvironment (TME) and genomic instability in shaping the tumor's behavior and therapeutic vulnerabilities. Key advancements, such as the identification of TP53 and BRCA mutations, the classification of homologous recombination repair (HRR) deficiencies, and the clinical implications of biomarkers like folate receptor alpha (FRα) and PD-L1 are discussed. These findings reveal actionable insights into targeted therapies, including immune checkpoint inhibitors and PARP inhibitors, which hold promise for improving outcomes in HGSOC. This synthesis of knowledge aims to bridge gaps in understanding HGSOC's multifaceted biology, enhance clinical decision-making, and foster the development of precision therapies.
AB - High-grade serous ovarian carcinoma (HGSOC) is the most aggressive subtype of epithelial ovarian cancer and a leading cause of mortality among gynecologic malignancies. This review aims to comprehensively analyze the morphological, immunohistochemical, and molecular features of HGSOC, highlighting its pathogenesis and identifying biomarkers with diagnostic, prognostic, and therapeutic significance. Special emphasis is placed on the role of tumor microenvironment (TME) and genomic instability in shaping the tumor's behavior and therapeutic vulnerabilities. Key advancements, such as the identification of TP53 and BRCA mutations, the classification of homologous recombination repair (HRR) deficiencies, and the clinical implications of biomarkers like folate receptor alpha (FRα) and PD-L1 are discussed. These findings reveal actionable insights into targeted therapies, including immune checkpoint inhibitors and PARP inhibitors, which hold promise for improving outcomes in HGSOC. This synthesis of knowledge aims to bridge gaps in understanding HGSOC's multifaceted biology, enhance clinical decision-making, and foster the development of precision therapies.
KW - BRCA
KW - Homologous recombination repair
KW - TILs
KW - P53
KW - TCGA
KW - Ovarian cancer
KW - BRCA
KW - Homologous recombination repair
KW - TILs
KW - P53
KW - TCGA
KW - Ovarian cancer
UR - http://hdl.handle.net/10807/311982
U2 - 10.1016/j.critrevonc.2024.104603
DO - 10.1016/j.critrevonc.2024.104603
M3 - Article
SN - 1879-0461
VL - 208
SP - 1
EP - 9
JO - CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY
JF - CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY
ER -